Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection

被引:34
作者
Toraño, JS
Verbon, A
Guchelaar, HJ
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Pharm, Pharmaceut & Toxicol Lab, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands
来源
JOURNAL OF CHROMATOGRAPHY B | 1999年 / 734卷 / 02期
关键词
thalidomide;
D O I
10.1016/S0378-4347(99)00345-X
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A validated and precise reversed-phase high-performance liquid chromatographic method for the determination of thalidomide in serum, with phenacetin as an internal standard, is described. Protein precipitation, using trichloroacetic acid, was used for clean-up. The aliquot was chromatographed on a octadecyl column, using an eluent composed of 250 ml 0.01 M potassium dihydrogenphosphate, adjusted to a pH of 3.0 with a 43% phosphoric acid solution, mixed with 750 ml methanol. Ultraviolet detection was used at an operation wavelength of 220 nm. Hydrolytic degradation was prevented during analysis by acidification of samples with the precipitation reagent. Thalidomide and phenacetin were found to have retention times of 7.9 and 15.0 min, respectively. Recoveries ranging from 79 to 84% were found for both components, with reproducibility relative standard deviations of 0.8-3% and repeatability coefficients of 1.2-3%. A mean correlation coefficient of 0.9995 was found for the linear calibration curve (n=2) of thalidomide with Limits of quantitation of 0.222-21 mg/l. The method appeared to be feasible for pharmacokinetic studies with thalidomide. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:203 / 210
页数:8
相关论文
共 10 条
[1]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY OF PLASMA THALIDOMIDE - STABILIZATION OF SPECIMENS AND DETERMINATION OF A TENTATIVE THERAPEUTIC RANGE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE [J].
BOUGHTON, BJ ;
SHEEHAN, TMT ;
WOOD, J ;
OBRIEN, D ;
BUTLER, M ;
SIMPSON, A ;
HALE, KA .
ANNALS OF CLINICAL BIOCHEMISTRY, 1995, 32 :79-83
[2]  
CHEN TL, 1989, DRUG METAB DISPOS, V17, P402
[3]   DETERMINATION OF THALIDOMIDE AND ITS MAJOR METABOLITES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
CZEJKA, MJ ;
KOCH, HP .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 413 :181-187
[4]   DETERMINATION OF THALIDOMIDE IN PLASMA AND BLOOD BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - AVOIDING HYDROLYTIC DEGRADATION [J].
ERIKSSON, T ;
BJORKMAN, S ;
FYGE, A ;
EKBERG, H .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 582 (1-2) :211-216
[5]   THALIDOMIDE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE [J].
HENEY, D ;
NORFOLK, DR ;
WHEELDON, J ;
BAILEY, CC ;
LEWIS, IJ ;
BARNARD, DL .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 78 (01) :23-27
[6]   DETERMINATION OF THALIDOMIDE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - METHODOLOGICAL STRATEGY FOR CLINICAL-TRIALS [J].
LYON, AW ;
DURAN, G ;
RAISYS, VA .
CLINICAL BIOCHEMISTRY, 1995, 28 (04) :467-470
[7]  
VOGELSANG GB, 1988, LANCET, V1, P827
[8]  
VOGELSANG GB, 1992, NEW ENGL J MED, V327, P735
[9]  
Wnendt S, 1996, CHIRALITY, V8, P390, DOI 10.1002/(SICI)1520-636X(1996)8:5<390::AID-CHIR6>3.3.CO
[10]  
2-4